<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117752</url>
  </required_header>
  <id_info>
    <org_study_id>225678-009</org_study_id>
    <nct_id>NCT02117752</nct_id>
  </id_info>
  <brief_title>Dermal Tolerability of Dapsone Gel in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the cumulative irritation potential and sensitization potential of
      dapsone gel and vehicle after repeat applications on the skin of healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Cumulative Irritation Index During Induction Phase</measure>
    <time_frame>21 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Sensitization Reactions During Challenge Phase</measure>
    <time_frame>6 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Dapsone Gel Subset 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapsone Gel Subset 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapsone gel</intervention_name>
    <description>Patches containing dapsone gel will be applied to the skin.</description>
    <arm_group_label>Dapsone Gel Subset 1</arm_group_label>
    <arm_group_label>Dapsone Gel Subset 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapsone gel vehicle</intervention_name>
    <description>Patches containing dapsone gel vehicle will be applied to the skin.</description>
    <arm_group_label>Dapsone Gel Subset 1</arm_group_label>
    <arm_group_label>Dapsone Gel Subset 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium lauryl sulfate</intervention_name>
    <description>Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.</description>
    <arm_group_label>Dapsone Gel Subset 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Patches containing normal saline (Negative Control) will be applied to the skin.</description>
    <arm_group_label>Dapsone Gel Subset 1</arm_group_label>
    <arm_group_label>Dapsone Gel Subset 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Healthy adults.

        Exclusion Criteria:

          -  Skin diseases, excessive hair, tattoos, pigmentation, scars or moles that could
             interfere with patch application

          -  Sensitivity to adhesive bandages or tape.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
